SCHEMBL5850209

SCHEMBL5850209

CC(C)c1c[nH]c(CC(=O)c2ccc(F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.40
NPC1 O15118 3/20 0.39
PTPN1 P18031 1/20 0.39
ALDH1A1 P00352 5/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTR7 P34969 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 2/20 0.39
PKM P14618 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
HSD11B1 P28845 2/20 0.36
PLOD2 O00469 1/20 0.36
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5850108 0.86 KDM4E (0.42) RAB9ANPC1PTPN1ALDH1A1MAPT
SCHEMBL5849986 0.78 PTPN1 (0.46) RAB9ANPC1PTPN1ALDH1A1MAPT
SCHEMBL28306998 0.75 RAB9A (0.40) RAB9ANPC1PTPN1ALDH1A1MAPT
SCHEMBL5093427 0.69 RAB9A (0.53) RAB9ANPC1PTPN1ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL5851860 0.69 RAB9A (0.47) RAB9ANPC1PTPN1ALDH1A1MAPT
SCHEMBL5850191 0.67 RAB9A (0.42) RAB9ANPC1PTPN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL5851298 0.66 RAB9A (0.44) RAB9ANPC1PTPN1ALDH1A1MAPT
SCHEMBL5635153 0.65 PTPN1 (0.52) RAB9ANPC1PTPN1ALDH1A1HTR7
SCHEMBL5851313 0.65 RAB9A (0.66) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL5444072 0.65 HTT (0.32) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984646-B2 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALHCARE AG (DE) 2006-01-10 US disclosed
EP-1412353-B1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2005-03-02 EP disclosed
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALTHCARE AG (DE) 2004-11-04 US disclosed
EP-1412353-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003008413-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors MAPK1, MAPK3, MAP3K1 RAB9A 1505/4885NPC1 2843/4885PTPN1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.